v3.26.3
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Gain (Loss)
Accumulated Deficit
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2023   26,597,000      
Stockholders' equity, beginning balance at Dec. 31, 2023 $ 88,103 $ 27 $ 702,969 $ (797) $ (614,096)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock from exercises of options and employee stock purchase plan (in shares)   364,000      
Issuance of common stock from exercises of options and employee stock purchase plan 6,473   6,473    
Issuance of common stock upon vesting of restricted stock units (in shares)   1,108,000      
Net share settlement of restricted stock units (in shares)   (347,000)      
Net share settlement of restricted stock units (7,504)   (7,504)    
Issuance of common stock (in shares)   2,751,000      
Issuance of common stock, net of $6,516 of transaction costs 93,877 $ 3 93,874    
Stock-based compensation 34,048   34,048    
Comprehensive income (loss) 1,102     1,102  
Net loss $ (145,231)       (145,231)
Stockholders' equity, ending balance (in shares) at Dec. 31, 2024 30,473,000 30,473,000      
Stockholders' equity, ending balance at Dec. 31, 2024 $ 70,868 $ 30 829,860 305 (759,327)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock from exercises of options and employee stock purchase plan (in shares)   732,000      
Issuance of common stock from exercises of options and employee stock purchase plan 14,291 $ 1 14,290    
Issuance of common stock upon vesting of restricted stock units (in shares)   356,000      
Net share settlement of restricted stock units (in shares)   (98,000)      
Net share settlement of restricted stock units (1,451)   (1,451)    
Repurchases and retirements of common stock (in shares)   (3,444,000)      
Repurchases and retirements of common stock (69,009) $ (3) (69,006)    
Stock-based compensation 36,072   36,072    
Comprehensive income (loss) (329)     (329)  
Net loss $ (13,232)       (13,232)
Stockholders' equity, ending balance (in shares) at Dec. 31, 2025 28,019,000 28,019,000      
Stockholders' equity, ending balance at Dec. 31, 2025 $ 37,210 $ 28 809,765 (24) (772,559)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock from exercises of options and employee stock purchase plan (in shares)   1,230,000      
Issuance of common stock from exercises of options and employee stock purchase plan 26,681 $ 2 26,679    
Issuance of common stock upon vesting of restricted stock units (in shares)   479,000      
Spin-off of First Tracks Biotherapeutics, net of tax (109,243)   (109,243)    
Tax effect on the gain from Spin-Off of First Tracks Biotherapeutics (96,227)   (96,227)    
Stock-based compensation 21,295   21,295    
Comprehensive income (loss) (127)     (127)  
Net loss $ 130,996       130,996
Stockholders' equity, ending balance (in shares) at Jun. 30, 2026 29,727,820 29,728,000      
Stockholders' equity, ending balance at Jun. 30, 2026 $ 10,585 $ 30 $ 652,269 $ (151) $ (641,563)